Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...
TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody ...
The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent ...
U.S. health experts this week will decide whether to recommend approval for Biogen Inc's Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as ...
The high-profile failure of Biogen’s Alzheimer’s disease drug aducanumab (Aduhelm), punctuated by the company’s decision in January 2024 to discontinue sales, highlights the common struggles faced by ...
James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the ...
The FDA's accelerated approval of aducanumab led to controversy and a congressional investigation, highlighting issues in the approval process. The HHS OIG report found deviations in 3 out of 24 drug ...
The BMJ is an international peer reviewed medical journal and a fully "online first" publication. Our publishing model–"continuous publication"– means that all articles appear on bmj.com before being ...
The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's experimental Alzheimer's drug aducanumab on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback